Cryotherapy Startup Arbel Medical in Second Round

Last month we reported on Core Dynamics, a company that develops technology to freeze human organs and increase their shelf life. Another Israeli startup, Arbel Medical, is developing office-friendly, next-generation , minimally invasive Cryo-therapy products for the treatment of breast tumors and other internal diseased tissue.

Founded in 2005, the company has previously raised $2.75 million in funding from Giza Venture Capital, Ofer Hi-Tech Ventures and TRD Instrum, and has now added an additional $450,000 from Bridge Investment Fund, which aims to set-up operations for Israeli life science companies in Cleveland, Ohio. Arbel is conducting trials in Cleveland and possibly opening offices there.

The company offers the following description of its flagship product IceSense:

“Cryotherapy is a fast-developing minimally-invasive procedure, in which a cryoprobe is used to ablate diseased tissue through the application of extreme cold.

IceSense™, Arbel’s breakthrough N2-based platform is adapted for use both in operating theaters and in freestanding clinics, offering the following key advantages over classical Joule-Thomson based products:

  • User friendliness (operation and maintenance) and reduced cost
  • Higher freezing capacity resulting in shorter treatment time
  • Easier control over the ablation process”

The company has future sights set on the growing area of women’s health, including using its IceSense technology in treating tumors from breast cancer, and also using it for aesthetic applications.


New Technology May Increase Organ Transplants

core-dynamics.gifIsraeli biotech company Core Dynamics has released the results of a study this month that demonstrate the feasibility of recovering a functional heart after it has been frozen and then thawed. Its unique controlled freezing method, which is based on the Company’s patented Multi Thermal Gradient (MTG) freezing technology, reduces the damage to cells caused by uncontrolled freezing techniques.

Founded in 1996 by Dr. Amir Arav, the cryopreservation company is hoping their solution will help address the tremendous shortage of donor organs, a problem which is exacerbated by the difficulty of maintaining organ viability until time of transplant. A human heart, for example, is restricted to just a few hours of harvest, transport and transplant time, which makes donor-recipient matching between remote locations extremely complicated. Due to these time constraints organ matching of all types of organs is limited to blood type and patient size.

freeze.jpgThe ability to prolong the shelf-life of donated organs would improve the quality of donor-recipient matching and increase the likelihood of receiving organs in any part of the world. Common post-transplant complications could also be reduced as a result of better matching.

Prof. Amir Elami from the Hadassah-Hebrew University Medical Center is hopeful: “These results are very encouraging.” “We believe that this achievement will lead to a time when we can bank cryopreserved organs in well-managed organ banks, and have ample time to assure we have the best match for the most critical-need patients.”

The research project was a joint effort between scientists at Core Dynamics and Hadassah-Hebrew University Medical Center in Jerusalem. The process is already being used today in niche applications in Eastern Europe, and the Company expects to begin marketing these uses in the U.S. shortly.

For more info see Core Dynamics’ press release.